Article
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Dec 2022
Dummer Reinhard, Flaherty Keith T, Robert Caroline, Arance Ana, de Groot Jan Willem B, Garbe Claus, Gogas Helen J, Gutzmer Ralf, Krajsová Ivana, Liszkay Gabriella, Loquai Carmen, Mandalà Mario, Schadendorf Dirk, Yamazaki Naoya, di Pietro Alessandra, Cantey-Kiser Jean, Edwards Michelle, Ascierto Paolo A
Abstract excerpt
PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453). METHODS: Patients with locally advanced unresectable or metastatic BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.